Evidence map›Paper›PMID 29967073›Full record

ArticleCancer discovery2018

Epistatic Oncogenic Interactions Determine Cancer Susceptibility to Immunotherapy.

Iñaki Etxeberria, Alvaro Teijeira, Luis M Montuenga, Pedro Berraondo, Ignacio Melero

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

  • Comment on
    2018
5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Iñaki EtxeberriaProgram of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.ORCID 0000-0003-2713-0836
Alvaro TeijeiraProgram of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
Luis M MontuengaNavarra Institute for Health Research (IDISNA), Pamplona, Spain.
Pedro BerraondoProgram of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.ORCID 0000-0001-7410-1865
Ignacio MeleroProgram of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain. imelero@unav.es.
Navarre Institute of Health Research · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Adenocarcinoma of LungProto-Oncogene Proteins p21(ras)AMP-Activated Protein Kinase KinasesHumansImmunotherapyMutationProgrammed Cell Death 1 ReceptorProtein Serine-Threonine KinasesAMP-Activated Protein Kinase KinasesKRAS protein, humanProgrammed Cell Death 1 ReceptorProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)STK11 protein, human

Identifiers

PMID29967073
OpenAlexW2811220493

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.